title: References - Neonatal Intensive Care Drug Manual
text: 1. Perry CM, Markham A. Piperacillin/Tazobactam. Drugs. 1999;57(5):805-43.
  2. John Jr JF, Davidson R, Low DE. Staphylococcus epidermidis and other coagulase-negative staphylococci. Antimicrobial therapy and vaccines E-Sun Technologies, Pittsburgh, PA. 2010.
  3. Cohen-Wolkowiez M, Watt KM, Zhou C, Bloom BT, Poindexter B, Castro L, et al. Developmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants. Antimicrobial agents and chemotherapy. 2014;58(5):2856-65.
  4. Salerno S, Hornik CP, Cohen-Wolkowiez M, Smith PB, Ku LC, Kelly MS, et al. Use of population pharmacokinetics and electronic health records to assess piperacillin-tazobactam safety in infants. The Pediatric infectious disease journal. 2017;36(9):855.
  5. Donadello K, Antonucci E, Cristallini S, Roberts JA, Beumier M, Scolletta S, et al. β-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: a case–control study. International journal of antimicrobial agents. 2015;45(3):278-82.
  6. Sherwin J, Heath T, Watt K. Pharmacokinetics and dosing of anti-infective drugs in patients on extracorporeal membrane oxygenation: a review of the current literature. Clinical therapeutics. 2016;38(9):1976-94.
  7. MIMS. Piperacillin/Tazobactam. (Accessed on 5 November 2020).
  8. Kalligeros M, Karageorgos SA, Shehadeh F, Zacharioudakis IM, Mylonakis E. The association of acute kidney injury with the concomitant use of vancomycin and piperacillin/tazobactam in children: A systematic review and meta-analysis. Antimicrobial Agents and Chemotherapy. 2019:AAC. 01572-19.
  9. Avedissian SN, Pais GM, Liu J, Rhodes NJ, Scheetz MH. Piperacillin-tazobactam added to vancomycin increases risk for acute kidney injury: fact or fiction? Clinical Infectious Diseases. 2020;71(2):426-32.
  10. Chen X-Y, Xu R-X, Zhou X, Liu Y, Hu C-Y, Xie X-F. Acute kidney injury associated with concomitant vancomycin and piperacillin/tazobactam administration: a systematic review and meta-analysis. International Urology and Nephrology. 2018;50(11):2019-26.
  11. Salerno SN, Liao Y, Jackson W, Greenberg RG, McKinzie CJ, McCallister A, et al. Association between Nephrotoxic Drug Combinations and Acute Kidney Injury in the Neonatal Intensive Care Unit. The Journal of Pediatrics. 2020.
  12. Australian Injectable Drugs Handbook, 8th Edition. Piperacillin and tazobactam. (Accessed on 5 November 2020.).
  13. Berger A, Kretzer V, Apfalter P, Rohrmeister K, Zaknun D, Pollak A. Safety evaluation of piperacillin/tazobactam in very low birth weight infants. Journal of chemotherapy. 2004;16(2):166-71.
  14. Kaye KS, Bhowmick T, Metallidis S, Bleasdale SC, Sagan OS, Stus V, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. Jama. 2018;319(8):788-99.
  |